Aztreonam Safe, Effective for Cystic Fibrosis Patients with PALS

A phase 3 clinical trial of inhalable Aztreonam (AZLI) in children up to 12 with CF and chronic P. aeruginosa infection in the lower airways (PALS) reported no safety issues, according to Gilead Sciences Inc. The results mean that AZLI could become a viable treatment for infection in CF patients in the near future.